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Abstract Several protein kinase C (PKC) isoforms are
expressed in human platelets. We report that PKC-N is tyrosine
phosphorylated within 30 s of platelet activation by thrombin.
This correlated with a 2^3-fold increase in the kinase activity of
PKC-N relative to unstimulated platelets. The tyrosine phos-
phorylated PKC-N isoform was associated with the platelet
particulate (100 000Ug insoluble) fraction. KIIbL3 integrin
mediated platelet adhesion to fibrinogen did not significantly
affect PKC-N activity. Tyrosine phosphorylation of PKC-N was
similarly not detected in fibrinogen adherent platelet lysates.
Treatment of the platelets with mAb 7E3 prior to the addition of
thrombin blocked aggregation having no effect on the thrombin
induced PKC-N activation. We conclude that PKC-N is activated
in platelets by an KIIbL3 independent pathway.
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1. Introduction
Protein kinase C (PKC) is a family of di¡erentially ex-
pressed serine/threonine kinases implicated in a diverse array
of cellular functions. The extended PKC family currently in-
cludes 12 structurally related isoenzymes [1^3]. Based on func-
tion and allosteric requirements, PKC isoforms are subdivided
into conventional/classical (cPKC; K, LI/LII, and Q), novel/
new (nPKC; N, O, R, and a) and atypical (aPKC; j, V, and
W) [4,5]. The cPKC are primarily activated by Ca2, diacyl-
glycerol, phospholipids, or phorbol esters. The nPKC lack the
Ca2 binding domain and are, therefore, Ca2 insensitive. The
aPKC are not a¡ected by diacylglycerol, phorbol esters, or
Ca2.
In platelets, PKC regulates multiple agonist stimulated re-
sponses including platelet shape change, secretion and aggre-
gation [6,7]. The platelet KIIbL3 integrin mediates platelet
spreading on ¢brinogen and the induction of tyrosine phos-
phorylation of the focal adhesion kinase, pp125FAK. The
involvement of PKC in this process has been demonstrated
in two ways. First, two pharmacological PKC inhibitors ab-
rogated both pp125FAK phosphorylation and platelet spread-
ing on ¢brinogen [8]. PKC inhibitors similarly prevented
pp125FAK phosphorylation in Chinese hamster ovary
(CHO) cells [9]. Second, platelet spreading and pp125FAK
phosphorylation are inhibited by several types of pharmaco-
logical agents including apyrase [10]. Treatment of the plate-
lets with phorbol 12-myristate 13-acetate (PMA), to directly
activate PKC, e¡ectively restored platelet spreading and
pp125FAK phosphorylation [10]. In contrast with these re-
sults, Ca2 chelators failed to a¡ect either pp125FAK phos-
phorylation or platelet spreading on ¢brinogen, raising the
possibility the KIIbL3-associated PKC is a Ca2 insensitive
PKC isoform [8].
PKC-N is the primary Ca2 insensitive PKC isoform iden-
ti¢ed in human platelets [11]. Baldassare et al. [11] have shown
that in thrombin stimulated platelets, PKC-K, -L, and -j, but
not PKC-N, translocated from the soluble to the particulate
fraction. From these data it was not possible to conclude
whether or not PKC-N was activated in platelets. The goal
of this study was, therefore, to examine whether thrombin
and/or the KIIbL3 integrin mediate PKC-N activation in plate-
lets. We report that PKC-N is activated and tyrosine phos-
phorylated in thrombin stimulated platelets, but not in plate-
lets adherent to ¢brinogen. Furthermore, KIIbL3 receptor
blockade did not a¡ect the induction of PKC-N phosphoryla-
tion. We therefore conclude that PKC-N activation in throm-
bin stimulated platelets is regulated by an KIIbL3 integrin in-
dependent pathway.
2. Materials and methods
2.1. Platelet preparation
Human platelets were puri¢ed from freshly drawn blood by gel
¢ltration as previously described [10]. For adhesion studies, polystyr-
ene plates were coated with ¢brinogen (100 Wg/ml; from Sigma).
Where indicated, the platelets were treated for 10 min with phorbol
ester (PMA) (10 nM; from Sigma) or with mAb 7E3 (10 Wg/ml), an
inhibitor of ¢brinogen binding to KIIbL3 and platelet aggregation,
kindly provided by Dr. Barry Coller (Mount Sinai School of Medi-
cine, New York).
2.2. Immunoprecipitation and immunoblotting
Suspended and adherent platelets were lysed for 20 min in Triton
lysis bu¡er (0.02% Triton X-100, 1 mM EGTA, 50 mM Tris pH 8.0,
1 mM sodium vanadate, and 0.5 mM PMSF). The lysates were clari¢ed
by centrifugation at 15 000Ug for 10 min at 4‡C, and were subse-
quently analyzed for protein content using the Pierce BCA reagents.
Equal amounts of protein were then subjected to immunoprecipita-
tion. The lysates were ¢rst pre-cleared for 1 h with protein A/G plus
agarose (from Santa Cruz) and then incubated with the antiserum to
PKC-N (nPKC-N C-20 from Santa Cruz, cat. # sc-937) for at least 2 h.
The immune complexes were precipitated with protein A/G plus agar-
ose. The immunoprecipitates prepared for Western blot analysis were
washed 4 times with RIPA bu¡er and eluted in Laemmli sample
bu¡er. Immunoprecipitates used for the kinase assay were processed
as described below. Immunoprecipitated proteins were examined by
immunoblotting with mAb 4G10 (from Upstate Biotechnology) which
speci¢cally interacts with tyrosine phosphorylated residues or the
PKC-N antiserum.
Total cell lysates were prepared by lysing the platelets in sample
bu¡er (66 mM Tris-HCl, pH 7.4, 2% SDS) at 90‡C. Lysates contain-
ing equal amounts of protein were subjected to immunoblot analysis
with mAb 4G10 or the PKC-N antiserum. Immunoreactivity was de-
tected using the ECL kit from Amersham and autoradiography.
Cytosolic and particulate fractions were generated as previously
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described [11]. Suspended platelets were stimulated with 5 U/ml
thrombin for 30 s to 20 min with stirring. At the indicated time the
platelets were lysed by the addition of a ¢fth volume of bu¡er con-
taining 125 mM Tris-HCl pH 7.5, 10 mM EDTA, 25 mM EGTA,
5 mM dithiothreitol, 10 mM PMSF, 0.1% Triton X-100, and 5 mM
vanadate (¢nal concentration 25 mM Tris-HCl pH 7.5, 2 mM EDTA,
5 mM EGTA, 1 mM dithiothreitol, 2 mM PMSF, 0.02% Triton X-
100, and 1 mM vanadate). All samples were sonicated with 4U10 s
pulses. Intact platelets and insoluble material were removed by cen-
trifugation at 12 000Ug for 2 min. Lysates were subsequently spun at
100 000Ug for 60 min. Supernatants (100 000Ug soluble) were recov-
ered and a fraction of each was subjected to immunoblotting analysis.
The pellets (100 000Ug insoluble) were resuspended in sample bu¡er
and were similarly subjected to immunoblotting analysis.
2.3. PKC-N immune complex kinase assay
PKC-N was immunoprecipitated as described above and the im-
mune complex kinase assays were performed using the kinase assay
kit from Upstate Biotechnology. Immune complexes bound to the
protein A/G agarose were washed once with 1 ml of bu¡er A (50
mM Tris, pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.1% 2-mercapto-
ethanol, 1% Triton X-100, 50 mM NaF, 5 mM sodium pyrophosphate,
10 mM sodium glycerophosphate, 1 mM sodium vanadate, and 1 mM
PMSF), once with 1 ml bu¡er A containing 0.5 M NaCl, and ¢nally
with 1 ml of assay dilution bu¡er (ADB) (20 mM MOPS, pH 7.2, 25
mM L-glycerophosphate, 5 mM EGTA, 1 mM sodium vanadate,
1 mM PMSF, and 1 mM dithiothreitol). Following the last wash,
the pelleted beads were resuspended in 30 Wl of ADB. The kinase
reaction was initiated with the addition of myelin basic protein (20
Wg/ml) and a magnesium/ATP cocktail (75 mM MgCl2 and 0.5 mM
ATP) containing 300 Ci/mmol [Q-32P]ATP (purchased from ICN Bio-
chemicals). A control sample included in each experiment contained
the immune complex and the kinase reaction components with the
exception of the substrate myelin basic protein. The reaction mixtures
were brie£y vortexed and incubated at 30‡C for 20 min with occa-
sional mixing. To terminate the kinase reaction, the beads were pel-
leted, and 15 Wl of the supernatant was spotted onto individual phos-
phocellulose ¢lters. The ¢lters were air-dried for 5 min, washed 3 times
in 0.75% of phosphoric acid and once in acetone, and subjected to
scintillation counting. Duplicate or triplicate samples were used for
each data point. The [Q-32P]ATP cpm counts bound to the ¢lter in the
absence of myelin basic protein were taken to represent background
and were accordingly subtracted from the values obtained for all
other samples. Data are expressed as a percent increase in cpm counts
relative to the unstimulated platelet lysate.
3. Results
3.1. Activation of platelet PKC-N by thrombin
Thrombin is a potent agonist that activates multiple signal-
ing pathways in platelets. We examined the induction of PKC-
N activation in response to treatment of suspended platelets
for 30 s to 30 min with 5 U/ml thrombin. The platelets were
subsequently lysed and lysates containing an equal protein
amount were divided into two fractions; one fraction contain-
ing 30^40 Wg protein was analyzed by immunoblotting. The
second fraction containing 400^500 Wg protein was immuno-
precipitated with the antiserum to PKC-N. Shown in Fig.
1A,B are the results of an immunoblot of total cell lysates
probed with mAb 4G10, speci¢c for phosphotyrosine residues,
and the PKC-N antiserum. Enhanced tyrosine phosphoryla-
tion of a protein that migrated with an electrophoretic mobi-
lity similar to that of PKC-N was seen within 30 s of thrombin
addition. Furthermore, as shown in Fig. 1C,D, PKC-N immu-
noprecipitated from platelet lysates activated with thrombin
for 30 s to 30 min was also tyrosine phosphorylated. Densito-
metric scanning of the gel shown in Fig. 1C revealed two
peaks of reactivity at 3 min and 20 min, respectively. In con-
trast, no tyrosine phosphorylation signal was associated with
PKC-N immunoprecipitated from unstimulated platelet lysates
(Fig. 1C,D, ¢rst and last lanes).
PKC-N activation was measured using an immune complex
kinase assay with myelin basic protein as a substrate. Data
were expressed as a fold increase relative to PKC-N activity
detected in unstimulated platelet lysates. As shown in Fig. 1E,
PKC-N activity increased about 2-fold within 30 s of thrombin
stimulation and remained elevated for 30 min. A biphasic
response such as the one shown in Fig. 1E was observed in
a total of four independent experiments, and is consistent with
the biphasic tyrosine phosphorylation pattern resolved
through densitometric analysis.
Baldassare et al. [11] have shown that when unstimulated
platelets are lysed in a low detergent containing bu¡er (0.02%
Triton X-100), about 90% of the total platelet PKC-K, L, and
j isoforms are released into the soluble fraction. In thrombin
stimulated platelets, a small part of each isoform redistributes
from the soluble to the particulate (100 000Ug insoluble) frac-
tion [11]. In contrast, about half of the total PKC-N popula-
tion was shown to be associated with the particulate fraction
both in resting and in thrombin activated platelets [11]. Data
shown in Fig. 1F con¢rm these observations, namely, that a
substantial portion of the total platelet PKC-N population was
associated with the particulate fraction whether the platelets
were stimulated or not. Furthermore, as shown in Fig. 1G,
tyrosine phosphorylation of a protein that co-migrated with
PKC-N was restricted to the particulate fraction. Tyrosine
phosphorylation of PKC-N may be limited to the membrane
fraction. Alternatively, PKC-N may undergo a rapid translo-
cation from the cytosol to the membrane fraction once tyro-
sine phosphorylated while the overall distribution of the PKC-
N population remains unchanged.
3.2. Di¡erential e¡ect of thrombin and ¢brinogen on PKC-N
tyrosine phosphorylation and activation
Having established that thrombin stimulates the induction
of PKC-N tyrosine phosphorylation and activation, we next
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Fig. 1. Time course of tyrosine phosphorylation and activation of PKC-N in thrombin activated platelets. Puri¢ed suspended platelets were un-
treated (UN; lane 1) or stirred in suspension with 5 U/ml thrombin for the times indicated. Platelets were then lysed in Triton X-100 bu¡er. In
A and B, unstimulated (lane 1) or thrombin stimulated (lanes 2^10) total platelet lysates containing 30^40 Wg protein were analyzed by immu-
noblotting with mAb 4G10 (A), or the antiserum to PKC-N (B). The arrow on the left indicates the position of PKC-N. In C and D, unstimu-
lated (lanes 1 and 12) or thrombin activated platelet lysates containing 400^500 Wg protein were immunoprecipitated with the antiserum to
PKC-N (lanes 1^10 and 12) or a control antiserum (lane 11). The immunoprecipitated proteins were Western blotted and probed with mAb
4G10 (C) or the antiserum to PKC-N (D). Data are representative of three experiments. In E, platelet lysates containing 400^500 Wg protein
were immunoprecipitated with the antiserum to PKC-N. The immunoprecipitated proteins were subjected to an in vitro kinase reaction with
myelin basic protein as substrate. The phosphorylated substrate was then spotted onto phosphocellulose ¢lters, washed, and subjected to scintil-
lation counting. Data are expressed as fold increase relative to unstimulated platelets. Shown is an average of two experiments, with duplicate
samples for each data point. In F and G, cytosol (100 000Ug soluble) and particulate (100 000Ug insoluble) fractions of unstimulated (UN;
lane 1) or platelets activated with thrombin for the indicated time (30 s to 20 min; lanes 2^5) were separated by high-speed centrifugation.
Fractions were analyzed by immunoblotting with the antiserum to PKC-N (F) or mAb 4G10 (G).
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examined the induction of PKC-N activation in platelets ad-
herent to ¢brinogen. Platelets were either stirred in suspension
with 5 U/ml thrombin for 5 or 10 min (in some experiments
the platelets were stimulated with 1 U/ml thrombin yielding
similar results), or were plated onto ¢brinogen-coated plates
for 30 min, the shortest time needed for all platelets to adhere
to the surface. The platelets were lysed and the lysates were
analyzed by Western blotting, immunoprecipitation, and im-
mune complex kinase assay as described above. As shown in
Fig. 2A^D, platelet adhesion to ¢brinogen failed to trigger the
induction of PKC-N tyrosine phosphorylation. The activity of
PKC-N isolated from ¢brinogen adherent platelets was not
statistically di¡erent from the activity measured in unstimu-
lated platelet lysates with an average of 1.5 þ 0.27 (n = 7;
P = 0.08) (Fig. 2E). The values for the platelets stimulated
with thrombin for 5 and 10 min, respectively, were
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Fig. 2. Di¡erential activation and tyrosine phosphorylation of PKC-N by thrombin or immobilized ¢brinogen. Platelets were kept in suspension
untreated (UN), stirred in suspension with 5 U/ml thrombin for 5 min or 10 min (THR 5P and THR 10P, respectively), or were added to ¢bri-
nogen (FBGN) coated plates for 30 min. In A and B, equal total protein amounts were analyzed by Western blotting with mAb 4G10 (A) or
the antiserum to PKC-N (B). The arrow on the left indicates the location of PKC-N. In C and D, platelet lysates containing 400^500 Wg protein
were immunoprecipitated with the antiserum to PKC-N (lanes 1^3 and lane 5) or a control antiserum (lane 4). The immunoprecipitated proteins
were immunoblotted and probed with mAb 4G10 (C) or the antiserum to PKC-N (D). In E, platelet lysates containing 400^500 Wg protein
were immunoprecipitated with the antiserum to PKC-N. The immunoprecipitated proteins were subjected to an in vitro kinase reaction and ana-
lyzed as described in the legend to Fig. 1. The data shown are an average of at least ¢ve experiments with duplicate or triplicate samples for
each data point.
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2.03 þ 0.22 (n = 7, P = 0.004) and 2.67 þ 0.38 (n = 4, P = 0.002).
These data indicated the platelet adhesion to ¢brinogen has
a very modest, if any, e¡ect on the induction of PKC-N activ-
ity.
3.3. E¡ect of an anti-KIIbL3 antibody on PKC-N activity
Although KIIbL3 appeared to be a poor mediator of PKC-N
activation we next asked whether KIIbL3 contributes to throm-
bin mediated PKC-N activation. For these studies, platelets
were treated with mAb 7E3, an inhibitor of ¢brinogen-
KIIbL3 interaction and platelet aggregation [12]. Treatment of
the platelets with mAb 7E3 prior to the addition of thrombin
blocked aggregation and pp125FAK phosphorylation [13],
having no e¡ect on the thrombin induced PKC-N activation
(Fig. 3); the PKC-N activity isolated from platelets treated
with mAb 7E3 prior to thrombin addition was 2.1 þ 0.13
(n = 3) and statistically insigni¢cant relative to platelets treated
with thrombin alone (2.25 þ 0.3). Thus, KIIbL3 appears not to
regulate PKC-N activation either on its own or when thrombin
is the stimulating agonist.
4. Discussion
In this study we demonstrate that PKC-N is activated and
tyrosine phosphorylated in thrombin stimulated platelets. We
also show that thrombin induced PKC-N activation is inde-
pendent of the KIIbL3 mediated signaling pathway. Baldassare
et al. [11] have shown that in thrombin stimulated platelets,
PKC-K, L, and j, but not PKC-N, translocated from the solu-
ble to the particulate fraction. These data provided no direct
evidence on whether PKC-N was activated or not. Data pre-
sented in this study clearly demonstrate that PKC-N is acti-
vated as well as tyrosine phosphorylated within 30 s of plate-
let activation by thrombin. The tyrosine phosphorylated
PKC-N isoform was associated with the platelet particulate
(100 000Ug insoluble) fraction.
In contrast with the e¡ect of thrombin on PKC-N activa-
tion, platelet adhesion to ¢brinogen had a minor, if any, e¡ect
on the activity of PKC-N. Tyrosine phosphorylation of PKC-N
was similarly not detected in lysates of ¢brinogen adherent
platelets. In Swiss 3T3 cells, Rho-A stimulated the recruitment
of both pp125FAK and PKC-N to focal adhesion plaques [14].
However, PKC-N was not localized to the focal adhesion
plaques either in ¢brinogen or phorbol ester treated ¢brinogen
adherent platelets (unpublished data). Finally, pretreatment of
the platelets with mAb 7E3, an inhibitor of KIIbL3-¢brinogen
interaction and as a consequence platelet aggregation [12] as
well as pp125FAK phosphorylation [13], did not a¡ect PKC-N
activation in response to thrombin. Taken together, these data
suggested that KIIbL3 does not mediate PKC-N tyrosine phos-
phorylation or activation.
A tyrosine phosphorylated PKC-N was identi¢ed in several
model systems including c-Ha-ras transformed ¢broblasts
[15,16], salivary gland epithelial cells [17], and phorbol ester
stimulated 32D cells (a murine interleukin-3 dependent mye-
loid progenitor line) that overexpress PKC-N [18]. The non-
speci¢c tyrosine kinase inhibitor, genistein, prevented PKC-N
tyrosine phosphorylation [17,18], while treatment of the 32D
PKC-N overexpressing cells with growth factors known to
trigger protein tyrosine phosphorylation, including insulin,
and EGF, failed to trigger PKC-N tyrosine phosphorylation
suggesting that this tyrosine phosphorylation event is speci¢c
and tightly regulated [17]. Src and, to a lesser extent, fyn have
been implicated in the induction of PKC-N tyrosine phospho-
rylation [19^21]. The relationship between tyrosine phospho-
rylation of PKC-N and its activation is not clear. Inhibitors
that block PKC autophosphorylation and thus its activation
did not prevent PKC-N phosphorylation on tyrosine. These
data suggested that PKC-N tyrosine phosphorylation and ac-
tivation represent independent events [16,19]. Studies in kera-
tinocytes, and v-src transformed ¢broblasts, suggested that
tyrosine phosphorylation may attenuate the activity of
PKC-N [20,21]. In contrast, studies with a baculovirus derived
PKC-N which was phosphorylated on tyrosine by di¡erent
tyrosine kinases, as well as studies with PDGF stimulated
32D cells, suggested that its kinase activity was increased as
a result of the phosphorylation [16].
The physiological role of the PKC-N isoform is also unclear
at the present time. PKC-N overexpression in NIH 3T3 cells
decreased the growth rate and prevented anchorage independ-
ent cell growth in soft agar [22]. Other studies have proposed
a role for PKC-N in macrophage [23,24], PC12 cell [25], and
keratinocyte di¡erentiation [20], and more recently in relation-
ship to apoptosis [26]. Based on these data it is possible that
PKC-N activation plays a critical role during megakaryocyte
di¡erentiation, having a secondary role, if any, relative to
platelet activation.
In summary, we found that platelet activation with throm-
bin results in rapid induction of tyrosine phosphorylation and
activation of PKC-N that is mediated via an KIIbL3 integrin
independent pathway. Further studies are required to estab-
lish the role of PKC-N in platelets.
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Fig. 3. E¡ect of KIIbL3 inhibitors on thrombin induced PKC-N acti-
vation. Platelets were kept in suspension untreated (UN), or were
stirred in suspension with 5 U/ml thrombin for 10 min. Prior to the
addition of thrombin, the samples were treated for 10 min with or
without mAb 7E3 (10 Wg/ml). Platelets were lysed in Triton X-100
bu¡er and were subjected to an in vitro kinase reaction as described
in the legend to Fig. 1.
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